Hualiang Jiang

This inventor holds 44 USPTO granted patents and 19 published patent applications, plus 18 CIPO patents and 26 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Chinese Academy of Sciences, Topharman Shanghai Co., Ltd., Suzhou Vigonvita Life Sciences Co., Ltd.. Active years: 2010-2026.

USPTO Granted Patents = 44 (Patent Applications = 19)

% Patents Active = 84.1

CIPO Patents = 18 (Patent Applications = 9)

EPO Patents = 26 (Patent Applications = 49)

Average Co-Inventor Count = 9.1

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

42 out of 3,334

Chinese Academy of Sciences

patents

5 out of 15

Topharman Shanghai Co., Ltd.

patents

3 out of 5

Suzhou Vigonvita Life Sciences Co., Ltd.

patents

4. 3 out of 10

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

patents

5. 2 out of 138

East China University of Science and Technology

patents

6. 2 out of 2

Suzhou Suplead Life Sciences Co., Ltd.

patents

7. 2 out of 4

Topharman Shandong Co., Ltd.

patents

8. 2 out of 2

Vigonvita Life Sciences Co., Ltd.

patents

9. 1 out of 7

Cisen Pharmaceutical Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Nanjing Pailexing Pharmaceutical Technology Ltd.

patent

14. 1 out of 1

Shanghai Institute of Materia Medica, Cas

patent

15. 1 out of 1

Shanghai Institute of Materia Medica, Chines Academy of Sciences

patent

16. 1 out of 1

Shanghai Lead Discovery Pharmaceuticals Limited Company

patent

17. 1 out of 1

Suzhou Institute of Materia Medica

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Acetylcholinesterase Inhibitor

DPPIV Inhibitor

Antiviral Applications

Nucleoside Analog

Histone Acetyltransferase

Pharmaceutical Composition

Tetrahydroisoquinoline

Saponin Compound

Autophagy Regulator

Heterocyclic Compounds

Chiral Ligand

PPAR Agonists

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636275 - Pharmaceutical use of ketoamide-based compound (2026-05-26),

2. 12590061 - Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof (2026-03-31),

3. 12497394 - Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof (2025-12-16),

4. 12351599 - Antiviral application of nucleoside analog or combination formulation containing nucleoside analog (2025-07-08),

5. 12172989 - Histone acetyltransferase (HAT) inhibitor and use thereof (2024-12-24),

6. 12152017 - Ketoamide compound and preparation method, pharmaceutical composition, and use thereof (2024-11-26),

7. 12145923 - Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof (2024-11-19),

8. 11919923 - Antiviral application of nucleoside analog or combination formulation containing nucleoside analog (2024-03-05),

9. 11873292 - Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof (2024-01-16),

10. 11731965 - Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition (2023-08-22),

11. 11730742 - Pharmaceutical use of thiophene [3,2-d] pyrimidine-4-ketone compound (2023-08-22),

12. 11529321 - Use of aminomethylenecyclohexane-1,3-dione compound (2022-12-20),

13. 11464795 - Saponin compound targeting PD-1 and application thereof (2022-10-11),

14. 11434226 - Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof (2022-09-06),

15. 11427593 - Bromodomain inhibitor compound and use thereof (2022-08-30),

Title: Hualiang Jiang: Pioneering the Field of Pharmaceutical Innovations in Shanghai

Introduction

Hualiang Jiang is a renowned inventor based in Shanghai, China, and holds an impressive portfolio of 40 patents. His work primarily focuses on the development of innovative pharmaceutical compounds and their applications in treating various diseases, showcasing his significant contributions to the biomedical field.

Latest Patents

Among Hualiang Jiang's latest patents are two notable inventions. The first patent details a histone acetyltransferase (HAT) inhibitor, which includes a range of compounds, such as stereoisomers, enantiomers, and polymorphs. This invention emphasizes its therapeutic potential in treating HAT-related diseases.

The second patent introduces a ketoamide compound and outlines its preparation method and pharmaceutical composition. This compound demonstrates efficacy in inhibiting viruses like the coronavirus and Ebola, indicating its potential role in preventing and treating diseases related to these pathogens.

Career Highlights

Hualiang Jiang has made significant strides in his career, being associated with prominent institutions and companies. He has worked at the Shanghai Institute of Materia Medica, which is part of the Chinese Academy of Sciences, as well as at Topharman Shanghai Co., Ltd. These positions have enabled him to collaborate on various innovative projects and further his research in pharmaceutical sciences.

Collaborations

Throughout his career, Hualiang Jiang has teamed up with several talented individuals. Notable among his collaborators are Kaixian Chen and Hong Tao Liu. Their combined expertise has undoubtedly contributed to the successful development of Jiang's impactful inventions.

Conclusion

Hualiang Jiang stands out as a significant figure in the realm of pharmaceuticals, with an impressive number of patents that exemplify his commitment to innovation. His work not only enhances our understanding of disease treatment but also underscores the importance of collaboration in scientific research. As he continues to develop novel compounds, Hualiang Jiang is likely to remain a key player in the pharmaceutical industry for years to come.